皓宸医疗(002622) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥27,295,409.54, a decrease of 4.51% compared to the same period last year, while year-to-date revenue increased by 31.22% to ¥76,394,047.11[6] - The net profit attributable to shareholders for Q3 2021 was a loss of ¥8,070,454.04, representing a decline of 271.41% year-on-year, while year-to-date net profit increased by 104.30% to ¥1,190,683.07[6] - Basic and diluted earnings per share for Q3 2021 were both -¥0.0096, a decrease of 271.41% compared to the same period last year, while year-to-date earnings per share increased by 104.24% to ¥0.0014[6] - Total operating revenue for Q3 2021 was CNY 76,394,047.11, an increase of 31.1% compared to CNY 58,217,553.26 in the same period last year[29] - Net profit for Q3 2021 was CNY 1,190,683.07, a significant recovery from a net loss of CNY 27,711,292.48 in Q3 2020[30] - Basic and diluted earnings per share for the quarter were both ¥0.0014, a recovery from a loss of ¥0.0330 per share in the previous year[31] - The total comprehensive income attributable to the parent company was -¥20,094,935.58, compared to -¥18,765,711.38 in the same period last year, reflecting a decline of about 7.1%[31] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥1,375,052,149.42, an increase of 2.57% from the end of the previous year[7] - The company's equity attributable to shareholders decreased by 2.31% to ¥850,968,343.79 compared to the end of the previous year[7] - The company's total assets reached CNY 1,375,052,149.42, compared to CNY 1,340,539,193.47 at the end of the previous quarter[27] - Current liabilities increased to CNY 434,561,291.61 from CNY 379,614,972.28 in the previous quarter[26] - The total equity attributable to shareholders was CNY 850,968,343.79, down from CNY 871,063,279.37 in the previous quarter[27] - The total liabilities stood at approximately ¥469.48 million, indicating a debt-to-equity ratio of about 54%[39] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥9,907,822.34, a decrease of 69.14% compared to the previous year[6] - The net cash flow from operating activities was ¥9,907,822.34, down from ¥32,107,785.48 in the previous year, indicating a decline of about 69.1%[34] - The cash inflow from operating activities totaled ¥81,268,842.35, down from ¥107,364,752.48 in the previous year, a decrease of approximately 24.3%[34] - The cash outflow from operating activities was ¥71,361,020.01, slightly lower than ¥75,256,967.00 in the previous year, indicating a decrease of about 5.3%[34] - The total cash and cash equivalents at the end of the period increased to ¥223,411,061.97, compared to ¥101,130,216.04 at the end of the previous year, representing a growth of approximately 120.5%[35] - The net cash flow from investment activities was ¥75,000,000.00, significantly higher than ¥30,055,072.05 in the previous year, marking an increase of about 149.2%[34] - The net cash flow from financing activities was -¥52,958,214.08, worsening from -¥32,365,343.73 in the same period last year, indicating a decline of approximately 63.8%[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 61,273[17] - The largest shareholder, Guangzhou Huiyin Rifeng Investment Partnership, holds 23.81% of shares, totaling 200,000,000 shares[17] Strategic Initiatives - The company plans to acquire 51% of Guangzhou Delun Medical Investment Co., Ltd. for a total cash consideration of 246 million RMB, with 141 million RMB for 30% from one party and 105 million RMB for 21% from another[19] - The assessed value of Delun Medical's total equity as of May 31, 2021, is approximately 569.62 million RMB[20] - The company aims to enhance its profitability by integrating high-quality assets, particularly through the acquisition of Delun Medical, which focuses on oral healthcare services[21] - The company is actively expanding into the oral healthcare service industry, which has significant market potential[21] - The upcoming shareholder meeting on November 11, 2021, will review the related matters of the asset acquisition[22] - The company has identified the need to improve its core business profitability to support sustainable development[21] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[30] Research and Development - Research and development expenses for Q3 2021 were CNY 6,098,463.04, compared to CNY 5,597,304.27 in Q3 2020, indicating a focus on innovation[30] Other Financial Metrics - Investment income decreased by ¥19,601,300, or 45.13%, due to reduced net profit from the company's associate, Fushun Bank[12] - The company experienced a 97.76% decrease in credit impairment losses compared to the same period last year, reflecting a reduction in provisions made in the previous year[13] - The company reported an investment income of CNY 23,828,877.58, a decrease from CNY 43,430,179.18 in the same period last year[30] - The company has not undergone an audit for the third quarter report, which may affect the reliability of the financial data presented[41]